Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 97-104 , April 2011

Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel

  • O. Ortmann

      Affiliations

    • Department of Gynaecology and Obstetrics, University of Regensburg, Germany
    • Corresponding Author InformationCorresponding author. Address: Department of Gynaecology and Obstetrics, University of Regensburg, Landshuter Strasse 65, D-93053 Regensburg, Germany. Tel.: +49 941 782 7511; fax: +49 941 782 7515.
    • ,
  • O. Pagani

      Affiliations

    • Institute of Oncology of Southern Switzerland, Bellinzona, Switzerland
    • ,
  • A. Jones

      Affiliations

    • Department of Clinical Oncology, Royal Free Hospital, London, UK
    • ,
  • N. Maass

      Affiliations

    • University Clinic for Gynaecology and Obstetrics, Aachen, Germany
    • ,
  • D. Noss

      Affiliations

    • Department of Gynaecology and Obstetrics, University of Regensburg, Germany
    • ,
  • H. Rugo

      Affiliations

    • University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
    • ,
  • C. van de Velde

      Affiliations

    • Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands
    • ,
  • Matti Aapro

      Affiliations

    • Clinique de Genolier, Genolier, Switzerland
    • ,
  • R. Coleman

      Affiliations

    • Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK

Received 24 March 2010 ,Revised 21 May 2010 ,Accepted 25 May 2010.

References 

  1. <http://seer.cancer.gov/statfacts/html/breast.html> [accessed 02.03.09].
  2. Tish Knobf M. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. The Oncologist. 2006;11:96–110
  3. <http://www.eurohealth.ie/newrep/trends.htm> [accessed 08.09.09].
  4. Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003;21:4184–4193
  5. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–1329
  6. Goodwin PJ. Options for preservation of fertility in women. N Engl J Med. 2005;353:1418–1420
  7. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–462
  8. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–570
  9. The BIG-1 98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen. N Engl J Med. 2009;361:766–776
  10. Regan MM, Pagani O, Walley B, et al. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol. 2008;19:1231–1241
  11. Peto R et al. Early Breast Cancer Trialists’ Collaborative Group. The worldwide overview: new results for systemic adjuvant therapies. San Antonio breast cancer symposium; 2007. p. A5.
  12. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  13. Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase inhibitors vs. tamoxifen for postmenopausal women with ER positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. San Antonio breast cancer symposium; 2008 [Abs. 12].
  14. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619–629
  15. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679–691
  16. Faddy MJ, Gosden RG. A mathematical model of follicle dynamics in the human ovary. Hum Reprod. 1995;10:770–775
  17. Randolph JF, Crawford S, Dennerstein L, et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrin Metab. 2006;91:3034–3040
  18. Burger HG, Hale GE, Robertson DM, et al. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women’s midlife health project. Hum Reprod Update. 2007;13:559–565
  19. Sowers MR, Zheng H, McConnell D, et al. Oestradiol rates of change in relation to the final menstrual period in a population-based cohort of women. J Clin Endocrin Metab. 2008;93:3847–3852
  20. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Stages of reproductive aging workshop (STRAW). J Women’s Health Gend Based Med. 2001;10:843–848
  21. Gracia CR, Sammel MD, Freeman EW, Lin H, Langan E, Kapoor S, et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause. 2005;12:128–135
  22. Prior JC. Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine. 2005;26:297–300
  23. Welt CK, Jimenez Y, Sluss PM, et al. Control of estradiol secretion in reproductive ageing. Hum Reprod. 2006;21:2189–2193
  24. Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93:3478–3483
  25. Breast cancer. NCCN practice guidelines in oncology v.2.; 2010.
  26. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24:5769–5779
  27. Swain SM, Jeong J-H, Geyer CE, et al. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. San Antonio breast cancer symposium; 2008 [Abs. 75].
  28. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 1999.
  29. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344:1997–2008
  30. Davis AL, Klitus M, Mintzer DM. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of addition of taxanes. Clin Breast Cancer. 2005;6:421–424
  31. Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma aged 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104:1575–1579
  32. Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30:126–132
  33. Di Cosimo S, Alimonti A, Ferretti G, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Ancol. 2004;15:1065–1071
  34. Smith IE, Dowsett M, Yap Y-S. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006;24:2444–2447
  35. Hargis JB, Nakajima ST. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors. Cancer Invest. 2006;24:174–177
  36. Requena A, Herrero J, Landeras J, et al. Use of letrozole in assisted reproduction: a systematic review and meta-analysis. Hum Reprod Update. 2008;14:571–582
  37. Mourits MJ, de Vries EG, Willemse PH, et al. Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer. 1999;79:1761–1764
  38. Mourits MJ, de Vries EG, ten Hoor KA, et al. Beware of amenorrhea during tamoxifen: it may be a wolf in sheep’s clothing. J Clin Oncol. 2007;25:3787–3788
  39. Ravdin PM, Fritz NF, Tormey DC, Jordan VC. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res. 1988;48:1021–1026
  40. Goss PE, Ingle JN, Martino S, et al. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. Cancer Res 2009;69S [Abs. 13].
  41. Jannuzzo MG, Di Salle E, Spinelli R, et al. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat. 2009;113:491–499
  42. Rossi E, Morabito A, De Maio E, et al. Endocrine effects of adjuvant letrozole+triptorelin compared with tamoxifen+triptorelin in premenopausal patients with early breast cancer. J Clin Oncol. 2008;26:264–270
  43. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK expert group. Cancer Treatment Rev. 2008;34(Suppl. 1):S3–S18
  44. Hadji P, Body J-J, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 2008;19:1407–1416

PII: S0305-7372(10)00104-0

doi: 10.1016/j.ctrv.2010.05.005

Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 97-104 , April 2011

Article Tools

* Image Usage & Resolution